A Study of HS-10380 in Chinese Participants

Hansoh Pharma logo

Hansoh Pharma

Status and phase

Enrolling
Phase 1

Conditions

Schizophrenia

Treatments

Drug: Placebo
Drug: HS-10380

Study type

Interventional

Funder types

Industry

Identifiers

NCT05480592
HS-10380-101

Details and patient eligibility

About

The primary objective of this study is to assess the safety and tolerability of single and multiple oral administered doses of HS-10380 in Chinese healthy subjects.

Full description

This is a phase I, randomized, double-blinded, placebo-controlled, both single ascending doses (SAD) study and multiple ascending dose (MAD) clinical trial to assess the safety, tolerability, and pharmacokinetics of HS-10380 in Chinese healthy subjects. There will be four phases in SAD and MAD study: a 2-week screening phase, a 1-day baseline phase, a double-blind treatment phase, and a 1-week post-treatment (follow-up) phase.

Enrollment

76 estimated patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy subject aged from 18 to 45 years;
  • Subject has a Body Mass Index (BMI) between 18.5 and 26.0 kg/m2 at screening and the weight of male subjects is not less than 50 kg, and the weight of female subjects is not less than 45 kg;
  • Voluntary subject who signs the informed consent form after understanding the purpose, content, process and possible risks of the trial;
  • Subject is able to communicate well with the investigator and comply with the lifestyle constraints specified in the protocol, and cooperate to complete the trial procedures.

Exclusion criteria

  • Subject has history or presence of disease or dysfunction affecting the clinical trial, including but not limited to neuropsychiatric system, cardiovascular system, urinary system, digestive system, respiratory system, musculoskeletal system, metabolic endocrine system, skin disease, blood system disease, immune system and tumor, etc.;
  • Subject has any surgical condition or condition that may significantly affect the absorption, distribution, metabolism, and excretion of the drug, or any surgical condition or condition that may pose a hazard to the subjects participating in the trial, such as gastrointestinal surgery (gastrectomy, Gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, peptic ulcer, history of gastrointestinal bleeding, etc.;
  • Subject has a history of significant drug allergies or known allergies to the components of the test drug;
  • Subject has history or presence of psychiatric disorders and cerebral dysfunction, or subjects at risk of suicide according to the Columbia Suicide Severity Rating Scale (C-SSRS) or at risk of suicide according to the investigator's clinical judgment, or has a history of self-harm;
  • Subject has a history of drug abuse within 1 year prior to screening, or has a positive urine drug result screen at screening;
  • Subject has history of alcohol abuse or a single consumption of more than 14 units of alcohol (1 unit = 285 mL of beer, 25 mL of spirits, 150 mL of wine) in the nearly one year prior to screening or a positive breath test for alcohol at screening;
  • Subject has smoked ≥5 cigarettes per day or consumed an average of ≥5 (200mL/cup) cups of coffee or tea per day in the 3 months before screening, or could not stop users during the study;
  • Subject has special requirements for food or is unwilling to accept a uniform diet or has difficulty swallowing;
  • Pregnant or breastfeeding women, or those who refuse to use effective contraception (eg, abstinence, IUD) throughout the study period and 6 months after the end of the study, or those who have a sperm or egg donation plan;
  • Subject has clinically significant abnormal comprehensive physical examination, vital signs, laboratory tests, and 12-lead electrocardiograms, which are judged by the investigator (eg: QTcF>450ms for men and >470ms for women, Friericia correction);
  • Subject with resting pulse rate <55 bpm or >100 bpm; systolic blood pressure <90mmHg or >140mmHg; diastolic blood pressure <60mmHg or >90mmHg at screening;
  • Subject has detectable hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV), or human immunodeficiency virus (HIV) antibody at screening;
  • Subject with alanine aminotransferase (ALT), creatinine (Cr), blood urea nitrogen (BUN) exceeding the upper limit of normal or serum prolactin greater than 2 times the upper limit of normal at the time of screening;
  • Subject has donated blood or lost blood ≥ 400ml within 3 months before screening, or donated blood or lost blood ≥ 200ml within one month, or has a history of using blood products;
  • Subject with a history of surgery within 3 months prior to screening, or who have not recovered from surgery, or who have anticipated surgery plans during the trial;
  • Subject has taken any medication within 2 weeks (or 5 half-lives, whichever is longer) prior to screening or takes any medication throughout study, including prescription and over-the-counter medications, Chinese herbal medicines, and any drugs that inhibit or induce liver drug metabolizing enzymes (such as inducers and/or inhibitors of CYP3A4, CYP2D6 and CYP3A5);
  • Subject has participated in any clinical trial or took any clinical trial drugs within 3 months before screening;
  • Subject has dieted or received dietary therapy, or had significant changes in dietary habits within 30 days prior to screening;
  • Subject has a history of vaccination within 30 days prior to screening, or has a vaccination schedule throughout the study;
  • Subject with poor compliance or other problems which the investigator considers unsuitable for subject to participate.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Quadruple Blind

76 participants in 2 patient groups, including a placebo group

Single Ascending Dose (SAD)
Experimental group
Description:
Subjects in cohorts 1-6 will receive oral administration of single dose of HS-10380 tablets or matching placebo.
Treatment:
Drug: HS-10380
Drug: Placebo
Multiple Ascending Dose (MAD)
Placebo Comparator group
Description:
Subjects in cohorts 7 will receive oral administration of 7 dose of HS-10380 tablets or matching placebo.
Treatment:
Drug: HS-10380
Drug: Placebo

Trial contacts and locations

1

Loading...

Central trial contact

Huafang Li, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems